Fig. 5
From: Targeting CRAF kinase in anti-cancer therapy: progress and opportunities
Combination therapies of CRAF/pan-RAF inhibitors and other treatments. Target therapies for CRAF/pan-RAF kinases (also refer to Table 3), including CRAF/pan-RAF inhibitors, Scaffold/chaperone proteins inhibitors, RAF RBD-RAS binding inhibitors, dual EGFR-RAF inhibitors, dual RAF-MEK inhibitors are illustrated above. Additionally, combination therapies of other treatments with CRAF/pan-RAF inhibitors, including RASG12C covalent inhibitors, EGFR inhibitors, MEK inhibitors, CDK inhibitors, Rb-CRAF inhibitors, PI3K inhibitors, STAT inhibitors, mTOR inhibitors, PD-1/PD-L1 antibodies, and CTLA-4 antibody are shown. EGFR, Epidermal Growth Factor Receptor; PI3K, Phosphoinositide 3-Kinase; STAT, Signal Transducer and Activator of Transcription; mTOR: Mammalian Target of Rapamycin; PD-1/PD-L1: Programmed Cell Death Protein 1/Programmed Death-Ligand 1; CTLA-4: Cytotoxic T-Lymphocyte-Associated Protein 4